Leerink Partnrs Predicts Gilead Sciences Q1 Earnings
Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...
FiercePharma2d
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
Stocktwits on MSN2d
Gilead Wins Price-Target Boosts After Solid Q4, Retail Brushes Off Medicare Reform Hit To HIV Drugs
Shares of Gilead Sciences Inc. surged over 4% in premarket trading on Wednesday following a solid fourth-quarter earnings ...
Gilead Sciences’ (GILD) Hold Rating Reiterated at Needham & Company LLC
Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...
Gilead Sciences Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a three-day winning streak.
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...
Gilead provides upbeat 2025 forecast, shares rise 4%
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Gilead Sciences (NASDAQ:GILD) Hits New 12-Month High on Earnings Beat
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...